CN106213515A - A kind of high bioavailability lycopene oral liquid product and preparation method - Google Patents
A kind of high bioavailability lycopene oral liquid product and preparation method Download PDFInfo
- Publication number
- CN106213515A CN106213515A CN201610587433.0A CN201610587433A CN106213515A CN 106213515 A CN106213515 A CN 106213515A CN 201610587433 A CN201610587433 A CN 201610587433A CN 106213515 A CN106213515 A CN 106213515A
- Authority
- CN
- China
- Prior art keywords
- lycopene
- liquid
- oral liquid
- bioavailability
- cis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000012661 lycopene Nutrition 0.000 title claims abstract description 168
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 title claims abstract description 167
- 239000001751 lycopene Substances 0.000 title claims abstract description 167
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 title claims abstract description 160
- 229960004999 lycopene Drugs 0.000 title claims abstract description 160
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 title claims abstract description 160
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 title claims abstract description 146
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 229940023492 oral liquid product Drugs 0.000 title claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 65
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000002245 particle Substances 0.000 claims abstract description 16
- -1 lycopene lipid Chemical class 0.000 claims abstract description 14
- 239000008187 granular material Substances 0.000 claims abstract description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 10
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims abstract description 9
- 239000000047 product Substances 0.000 claims abstract description 9
- OAIJSZIZWZSQBC-UHFFFAOYSA-N (7Z,9Z,7'Z,9'Z)-ψ,ψ-carotene Chemical compound CC(C)=CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC=C(C)CCC=C(C)C OAIJSZIZWZSQBC-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000001054 red pigment Substances 0.000 claims abstract description 6
- 240000003768 Solanum lycopersicum Species 0.000 claims abstract description 4
- 238000006243 chemical reaction Methods 0.000 claims abstract description 3
- 239000000839 emulsion Substances 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 239000003921 oil Substances 0.000 claims description 11
- 235000019198 oils Nutrition 0.000 claims description 11
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 230000001804 emulsifying effect Effects 0.000 claims description 8
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 7
- 230000004087 circulation Effects 0.000 claims description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 7
- 229920000053 polysorbate 80 Polymers 0.000 claims description 7
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 241000227653 Lycopersicon Species 0.000 claims description 5
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 5
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 5
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 4
- 229940049654 glyceryl behenate Drugs 0.000 claims description 4
- 239000003549 soybean oil Substances 0.000 claims description 4
- 235000012424 soybean oil Nutrition 0.000 claims description 4
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 abstract description 7
- OAIJSZIZWZSQBC-UMONDHTKSA-N (6e,8z,10e,12z,14e,16z,18e,20z,22e,24z,26e)-2,6,10,14,19,23,27,31-octamethyldotriaconta-2,6,8,10,12,14,16,18,20,22,24,26,30-tridecaene Chemical class CC(C)=CCC\C(C)=C\C=C/C(/C)=C/C=C\C(\C)=C\C=C/C=C(\C)/C=C\C=C(/C)\C=C/C=C(\C)CCC=C(C)C OAIJSZIZWZSQBC-UMONDHTKSA-N 0.000 abstract description 4
- 239000004005 microsphere Substances 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 235000013305 food Nutrition 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- WSGYTJNNHPZFKR-UHFFFAOYSA-N 3-hydroxypropanenitrile Chemical compound OCCC#N WSGYTJNNHPZFKR-UHFFFAOYSA-N 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002664 lycopenes Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000008601 oleoresin Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A kind of high bioavailability lycopene oral liquid product and preparation method.Invention uses nitrogen protection, high temperature thermosoling improves lycopene dissolubility in oil phase, promote the all-trans lycopene conversion to cis-configuration lycopene and then improve cis-configuration lycopene accounting, prepare the particle size range of lycopene lipid granule 100～300nm, content of lycopene is 8～22mg/10mL, cis-configuration lycopene accounts for the ratio of lycopene total amount and reaches more than 50%, its bioavailability is the lycopene oral liquid product of more than 3 times of Lycopersicon esculentum red pigment goods, there is content of lycopene high, All-cislycopene isomer accounting is high, lycopene bioavailability is high, lipid microsphere particle diameter is little, the feature of oral liquid constant product quality.
Description
Technical field
The present invention relates to a kind of high bioavailability lycopene oral liquid product and preparation method thereof, it is characterized in that product
The particle size range of middle lycopene lipid granule is 100～300nm, and content of lycopene is 8～22mg/10mL, cis-configuration
Lycopene accounts for the ratio of lycopene total amount and reaches more than 50%, and the bioavailability of lycopene is Lycopersicon esculentum red pigment system
Product more than 3 times；The bioavailability of every lycopene oral liquid (10mL) is equivalent to the flexible glue containing lycopene 24～66mg
Capsule or tabletting.Belong to technical field of health-care food production.
Background technology
Lycopene be one have antioxidation, strengthen body immunity, to contribute to alleviating prostatic hyperplasia symptom etc. many
Plant the carotenoid of physiological function, be widely used in the field such as health food, cosmetics.Owing to lycopene molecule is in essence
On be the alkene containing a large amount of double bonds (11 conjugated double bonds and two unconjugated double bonds), there is strong hydrophobicity, water base
Food or health food (such as oral liquid) add and faces the technical difficulties such as lycopene stable suspersion, thus at present with tomato red
Element is the form such as soft capsule, tabletting for the health food overwhelming majority of outstanding feature composition.
Lycopene oral liquid should be a kind of stable oil in water dispersion system.Fat in this system, containing lycopene
Matter (being called for short lycopene lipid) particle is microsphere dispersity.The size of these lipid microsphere particle diameters is stablized with dispersion
The bioavailability of property and lycopene is closely related.National inventing patent CN 105166880 A discloses a kind of selection and contains
The oleoresin of natural lycopene is the oral liquor of raw material, and wherein lycopene mass content is not clear and definite, but combines
Its claim and description related content calculate, content of lycopene be about 0.275～1.425% (description [0004]: kind
Lycopene content be 0.5～1.5% Fructus Lycopersici esculenti extract aqueous solution mix with fructus lycii extracted solution, accounting for of Fructus Lycopersici esculenti extract aqueous solution
Ratio is 55～95%)；The particle diameter of undeclared lycopene lipid granule in literary composition, but by its technique (description [0004]: cut at a high speed
Machine of cutting is sheared 5～30 minutes, shear rate 1500～20000 revs/min, then through high pressure homogenizer homogenizing, processes to institute's dispensing
Complete, Stress control 40～80MPa), in conjunction with food processing experience, its particle diameter is typically 400～1000nm；Literary composition is also not directed to
The steric configuration of lycopene, by its technique be emulsifying infer, in product, the accounting of cis-configuration lycopene is with general
Logical suitable containing lycopene fabricated product, substantially 5～less than 12% (Pierre Lambelet etal.Improving the
stability of lycopene Z-isomers in isomerised tomato extracts,Food Chemistry
112(2009)156–161)。
It is true that the steric configuration of lycopene is directly related with its biological value, the lycopene of cis-configuration is more easy to
Be absorbed by the body (Cooperstone JL, etal.Enhanced bioavailability of lycopene when
consumed as cis-isomers from tangerine compared to red tomato juice,a
randomized,cross-over clinical trial.Mol.Nutr.Food Res.59(2015)658-69.).And work as
When the particle diameter of composition of food is less than 100nm, the chance of its turnover human body cell is significantly increased, it is understood that there may be bigger security risk
(Liu Jun, " nanometer food " safety leaves a question open, Guangzhou Daily JIUYUE 30 in 2010 the 033rd edition).
Therefore, research and development content of lycopene is moderate, lycopene lipid particle diameter appropriateness (100nm and more than), cis
Configuration lycopene accounting high (to improve its biological value), oral liquid product with lycopene as main active have
Significance.
Summary of the invention
It is an object of the invention to overcome the deficiency of existing product, be former with the purity all-trans lycopene more than 90%
Material, uses nitrogen protection, high temperature thermosoling to improve lycopene dissolubility in oil phase, promote that all-trans lycopene is to suitable
The conversion of formula configuration lycopene and then raising cis-configuration lycopene accounting, prepare the particle diameter of lycopene lipid granule
Scope is 100～300nm, and content of lycopene is 8～22mg/10mL, and cis-configuration lycopene accounts for lycopene total amount
The lycopene oral liquid that ratio reaches more than 50%, lycopene bioavailability is more than 3 times of Lycopersicon esculentum red pigment goods
Product, has content of lycopene height, All-cislycopene isomer accounting height, and lipid microsphere particle diameter is little, oral liquid quality is steady
Fixed feature.
Technical scheme is as follows:
The preparation method of lycopene oral liquid, step is as follows:
(1) at 75 DEG C, the Tween80 aqueous solution preheating that mass percent is 1%～2% is obtained A liquid；
(2) monoglyceride, lycopene, liquid glycerin three fat are joined in light resistant container, through nitrogen protection, stir and add
Heat (120～140 DEG C, 1～2min) obtains B liquid；
(3) in room temperature with under being stirred vigorously, A liquid is added rapidly in B liquid, is further continued for stirring 2min；
(4) by the mixed liquor of step (3) through high speed shear emulsifying (10000～16000r/min, 1.5～2.5min),
To pre-emulsion；
(5) pre-emulsion obtained in step (4) is obtained lycopene breast through high pressure homogenize (30～50MPa, 3 circulations)
Liquid；
(6) the lycopene emulsion that will obtain in step (5), under 4 DEG C of water bath condition, cools down rapidly, obtains tomato red
Element oral liquid.
Described monoglyceride is the one in glyceryl monostearate or single Glyceryl Behenate；
Described liquid glycerin three fat is in decanoyl/octanoyl glycerides, olive oil, soybean oil, Semen Maydis oil, Semen Lini oil
Kind；
Monoglyceride is 2 100～5 100 with the mass ratio of water；
Lycopene is 1 1000～2.5 1000 with the mass ratio of water；
Liquid glycerin three fat is 1 100～2 100 with the mass ratio of water；
Beneficial effects of the present invention
The present invention with monoglyceride as Solid lipid, common triglyceride as liquid fatty substance, use under nitrogen atmosphere protection
Thermosol process promotes that in Solid lipid and liquid fatty substance, the steric configuration of lycopene converts to cis-configuration from alltrans, so
Originally it was that the lycopene of crystalline state is converted into amorphous structure, lycopene dissolubility in lipid and life can be greatly improved
Thing availability；By shearing pre-emulsification, high pressure homogenize to improve the stability of oral liquid.
Lycopene oral liquid prepared by the present invention, wherein the particle size range of lycopene lipid granule 100～
300nm, content of lycopene is 8～22mg/10mL, and cis-configuration lycopene accounts for the ratio of lycopene total amount and reaches 50%
Above, the bioavailability of lycopene contained therein is commonly contain lycopene goods more than 3 times, efficiently solves Fructus Lycopersici esculenti
Red pigment is difficult in aqueous-based food that stable suspersion, particle diameter too small exist edible safety hidden danger, All-cislycopene accounting is low causes
The defects such as biological value is low, have the advantages that preparation technology is simple, steady quality, bioavailability are high, are suitable for industrialized production.
Accompanying drawing explanation
Fig. 1. the HPLC spectrogram (Figure 1A) of lycopene raw material used by embodiment 4 (content of lycopene is 91.2%) and institute
Lycopene HPLC spectrogram (Figure 1B) in the oral liquid of preparation.
From fig. 1, it can be seen that lycopene raw material is configured as main with alltrans, its ratio accounting for lycopene total amount reaches
96.2%, and cis-configuration lycopene accounting is only 3.8%；In prepared oral liquid, cis-configuration lycopene is the most
In all-trans lycopene, total All-cislycopene relative amount is 56.37%, and all-trans lycopene accounting is only
43.63。
Fig. 2. the oral liquid obtained in the embodiment of the present invention 4, measure gained grain size distribution through nano particle size instrument.
As shown in Figure 2, prepared lycopene oral liquid mean diameter is 197.2nm, and sample is homogeneous water-dispersible
System.
Detailed description of the invention
For a better understanding of the present invention, below in conjunction with embodiment, the present invention is described in further detail, but the present invention
Claimed scope is not limited to the scope that embodiment is limited；The lycopene raw material percent mass used in each embodiment
Number is 91.2%, and it is 3.8% that cis-configuration lycopene accounts for the ratio of lycopene total amount.
Embodiment 1
(1) at 75 DEG C, the Tween80 aqueous solution 100mL preheating that mass percent is 1% is obtained A liquid；
(2) 2g glyceryl monostearate, 100mg lycopene, 1g decanoyl/octanoyl glycerides are joined in light resistant container, warp
Nitrogen protection, stir and heat (120 DEG C, 2min) and obtain B liquid；
(3) in room temperature with under being stirred vigorously, A liquid is added rapidly in B liquid, is further continued for stirring 2min；
(4) by the mixed liquor of step (3) through high speed shear emulsifying (10000r/min, 1.5min), pre-emulsion is obtained；
(5) pre-emulsion obtained in step (4) is obtained lycopene emulsion through high pressure homogenize (30MPa, 3 circulations)；
(6) the lycopene emulsion that will obtain in step (5), under temperature is 4 DEG C of water bath condition, cools down rapidly, obtains
Lycopene oral liquid, wherein content of lycopene is 8.2mg/10mL, and cis-configuration lycopene accounts for lycopene total amount
Ratio is 50.5%, and lycopene lipid granule mean diameter is 210.8nm.
Embodiment 2
(1) at 75 DEG C, the Tween80 aqueous solution 100mL preheating that mass percent is 2% is obtained A liquid；
(2) mono-for 5g Glyceryl Behenate, 250mg lycopene, 2g olive oil are joined in light resistant container, protect through nitrogen
Protect, stir and heat (140 DEG C, 1min) and obtain B liquid；
(3) in room temperature with under being stirred vigorously, A liquid is added rapidly in B liquid, is further continued for stirring 2min；
(4) by the mixed liquor of step (3) through high speed shear emulsifying (16000r/min, 2.5min), pre-emulsion is obtained；
(5) pre-emulsion obtained in step (4) is obtained lycopene emulsion through high pressure homogenize (50MPa, 3 circulations)；
(6) the lycopene emulsion that will obtain in step (5), under temperature is 4 DEG C of water bath condition, cools down rapidly, obtains
Lycopene oral liquid, wherein content of lycopene is 20.1mg/10mL, and cis-configuration lycopene accounts for lycopene total amount
Ratio is 52.62%, and lycopene mean diameter is 150.3nm.
Embodiment 3
(1) at 75 DEG C, the Tween80 aqueous solution 100mL preheating that mass percent is 1.5% is obtained A liquid；
(2) 3g glyceryl monostearate, 200mg lycopene, 1.5g soybean oil are joined in light resistant container, through nitrogen
Protection, stir and heat (130 DEG C, 1.5min) and obtain B liquid；
(3) in room temperature with under being stirred vigorously, A liquid is added rapidly in B liquid, is further continued for stirring 2min；
(4) by the mixed liquor of step (3) through high speed shear emulsifying (16000r/min, 2.5min), pre-emulsion is obtained；
(5) pre-emulsion obtained in step (4) is obtained lycopene emulsion through high pressure homogenize (40MPa, 3 circulations)；
(6) the lycopene emulsion that will obtain in step (5), under temperature is 4 DEG C of water bath condition, cools down rapidly, obtains
Lycopene oral liquid, wherein content of lycopene is 16.5mg/10mL, and cis-configuration lycopene accounts for lycopene total amount
Ratio is 49.85%, and the mean diameter of lycopene lipid granule is 162nm.
Embodiment 4
(1) at 75 DEG C, the Tween80 aqueous solution 100mL preheating that mass percent is 2% is obtained A liquid；
(2) mono-for 3g Glyceryl Behenate, 250mg lycopene, 1.5g Semen Maydis oil are joined in light resistant container, through nitrogen
Protection, stir and heat (140 DEG C, 1.5min) and obtain B liquid；
(3) in room temperature with under being stirred vigorously, A liquid is added rapidly in B liquid, is further continued for stirring 2min；
(4) by the mixed liquor of step (3) through high speed shear emulsifying (12000r/min, 2min), pre-emulsion is obtained；
(5) pre-emulsion obtained in step (4) is obtained lycopene emulsion through high pressure homogenize (50MPa, 3 circulations)；
(6) the lycopene emulsion that will obtain in step (5), under temperature is 4 DEG C of water bath condition, cools down rapidly, obtains
Lycopene oral liquid.Wherein content of lycopene is 19.8mg/10mL, and cis-configuration lycopene accounts for lycopene total amount
Ratio is 56.37%, and the mean diameter of lycopene lipid granule is 197.2nm.
Embodiment 5
(1) at 75 DEG C, the Tween80 aqueous solution 100mL preheating that mass percent is 2% is obtained A liquid；
(2) 2.5g glyceryl monostearate, 150mg lycopene, 1.5g Semen Lini oil are joined in light resistant container, warp
Nitrogen protection, stir and heat (130 DEG C, 1.5min) and obtain B liquid；
(3) in room temperature with under being stirred vigorously, A liquid is added rapidly in B liquid, is further continued for stirring 2min；
(4) by the mixed liquor of step (3) through high speed shear emulsifying (16000r/min, 2min), pre-emulsion is obtained；
(5) pre-emulsion obtained in step (4) is obtained lycopene emulsion through high pressure homogenize (40MPa, 3 circulations)；
(6) the lycopene emulsion that will obtain in step (5), under temperature is 4 DEG C of water bath condition, cools down rapidly, obtains
Lycopene oral liquid, wherein content of lycopene is 12.1mg/10mL, and cis-configuration lycopene accounts for lycopene total amount
Ratio is 52.64%, and the mean diameter of lycopene lipid granule is 240.5nm.
Attached:
1. content of lycopene measures and the assay method of different spaces configuration lycopene accounting
The HPLC detection of lycopene: in the centrifuge tube of 10mL, is separately added into the lycopene prepared by 0.5mL and is administered orally
Liquid and 2mL ethyl acetate；Through water bath sonicator breakdown of emulsion and centrifugal after, take upper strata ethyl acetate in 10mL brown volumetric flask, so
Lycopene during use 2mL ethyl acetate continues extraction oral liquid the most respectively 2 times, is finally settled to 10mL by amalgamation liquid, uses
After 0.22 μm membrane filtration, with chromatograph of liquid, at 472nm, detect each isomery in lycopene respectively with area normalization method
Body percentage contents, and combine the content of lycopene in the quantitative oral liquid of all-trans lycopene standard curve.Chromatographic column:
YMC C30 post (5 μm, 250mm × 4.6mm)；Flowing phase: A phase: methanol acetonitrile=25 75, B phase: methyl tertiary butyl ether(MTBE)
100%；Gradient condition: 0～20m in, A phase is reduced to 50% by 100%, and 20～40min, A phase keeps 50%；Sample solvent:
Ethyl acetate；Flow velocity: 1mL/min；Column temperature: 30 DEG C；Sample size: 20 μ L.
2. the mensuration of lycopene lipid particle diameter in oral liquid
Employing is furnished with the Nano-ZS90 particle size analyzer of He/Ne laser instrument (λ=633nm), and angle of scattering is 90 °.By Fructus Lycopersici esculenti
After red pigment oral liquid diluted sample suitable multiple, it is loaded in polystyrene cuvette (refraction index 1.33) subsequently, (25 ±
0.1) it is incubated 3min at DEG C, measures, record mean diameter.3. lycopene Evaluation On The Bioavailability method
" diffusion model method " with reference to foundation such as D.Page evaluates bioavailability (the Kinetics of of lycopene
temperature increase during tomato processing modulate the bioaccessibility
of lycopene.Food Chemistry 135(2012)2462–2469).Should " diffusion model method " be based on lycopene quilt
Before the micelle being transferred in small intestinal, it is necessary to be first dissolved to this principle in lipid, calculate containing 5 milligrams of lycopene oral liquids or contain
The raw material of 5 milligrams of lycopenes to soybean oil and containing 0.1% dexycholate water mixture in, shaking 5Min after, enter
To the mass ratio of the lycopene of oil phase, as the index investigating lycopene bioavailability.
During lycopene prepared by this case embodiment 1 is oral, the bioavailability of lycopene is etc. that quality is raw materials used
3.67 times of lycopene.
Claims (5)
1. a high bioavailability lycopene oral liquid product, is characterized in that the particle diameter of lycopene lipid granule in product
Scope is 100～300nm, and content of lycopene is 8～22mg/10mL, and cis-configuration lycopene accounts for lycopene total amount
Ratio reaches more than 50%, and wherein the bioavailability of lycopene is more than 3 times of Lycopersicon esculentum red pigment.
2. a preparation method for high bioavailability lycopene oral liquid product, is characterized in that using nitrogen protection, high temperature
Thermosoling improves lycopene dissolubility in oil phase, promotes the all-trans lycopene conversion to cis-configuration lycopene
And then improve cis-configuration lycopene accounting, prepare cis-configuration lycopene in lycopene lipid granule and account for tomato red
The ratio of element total amount reaches more than 50%, and in product, the bioavailability of lycopene is commonly contain lycopene goods 3 times
Above.
3. the preparation method of high bioavailability lycopene oral liquid product based on claim 2, its concrete preparation process
As follows:
(1) at 75 DEG C, the Tween80 aqueous solution preheating that mass percent is 1%～2% is obtained A liquid；
(2) monoglyceride, lycopene, liquid glycerin three fat are joined in light resistant container, through nitrogen protection, stir and heat
(120～140 DEG C, 1～2min) obtain B liquid；
(3) in room temperature with under being stirred vigorously, A liquid is added rapidly in B liquid, is further continued for stirring 2min；
(4) by the mixed liquor of step (3) through high speed shear emulsifying (10000～16000r/min, 1.5～2.5min), obtain pre-
Emulsion；
(5) pre-emulsion obtained in step (4) is obtained lycopene emulsion through high pressure homogenize (30～50MPa, 3 circulations)；
(6) the lycopene emulsion that will obtain in step (5), under 4 DEG C of water bath condition, cools down rapidly, obtains lycopene mouth
Take liquid.
4. the preparation method of high bioavailability lycopene oral liquid product based on claim 3, described monoglyceride is
One in glyceryl monostearate or single Glyceryl Behenate；Described liquid glycerin three fat is decanoyl/octanoyl glycerides, Fructus Canarii albi
One in oil, soybean oil, Semen Maydis oil, Semen Lini oil.
5. the preparation method of high bioavailability lycopene oral liquid product based on claim 3, described monoglyceride with
The mass ratio of water is 2 100～5 100；Lycopene is 1 1000～2.5 1000 with the mass ratio of water；Liquid glycerin three fat
It is 1 100～2 100 with the mass ratio of water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610587433.0A CN106213515A (en) | 2016-07-22 | 2016-07-22 | A kind of high bioavailability lycopene oral liquid product and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610587433.0A CN106213515A (en) | 2016-07-22 | 2016-07-22 | A kind of high bioavailability lycopene oral liquid product and preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106213515A true CN106213515A (en) | 2016-12-14 |
Family
ID=57532689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610587433.0A Pending CN106213515A (en) | 2016-07-22 | 2016-07-22 | A kind of high bioavailability lycopene oral liquid product and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106213515A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109700025A (en) * | 2018-12-14 | 2019-05-03 | 晨光生物科技集团股份有限公司 | A kind of preparation method and its oil suspending agent of lycopene oil suspending agent |
| CN114451550A (en) * | 2021-12-21 | 2022-05-10 | 江苏艾兰得营养品有限公司 | Lutein defect type nano-structure lipid carrier and preparation method thereof |
| CN115812960A (en) * | 2022-11-09 | 2023-03-21 | 黑龙江八一农垦大学 | Preparation method of oil-based high-solubility non-oxygen-containing carotenoid |
| CN115844015A (en) * | 2022-12-06 | 2023-03-28 | 南昌大学 | Lycopene oil, lycopene preparation and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813256A (en) * | 2012-07-03 | 2012-12-12 | 江南大学 | Clear tomato juice beverage product for reinforcing lycopene and preparation method |
| CN105595358A (en) * | 2016-01-14 | 2016-05-25 | 青岛农业大学 | Extraction method and application of lycopene |
-
2016
- 2016-07-22 CN CN201610587433.0A patent/CN106213515A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813256A (en) * | 2012-07-03 | 2012-12-12 | 江南大学 | Clear tomato juice beverage product for reinforcing lycopene and preparation method |
| CN105595358A (en) * | 2016-01-14 | 2016-05-25 | 青岛农业大学 | Extraction method and application of lycopene |
Non-Patent Citations (1)
| Title |
|---|
| 蒲晓璐等: ""纳米食品的安全性及研究进展"", 《农产品加工 创新版》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109700025A (en) * | 2018-12-14 | 2019-05-03 | 晨光生物科技集团股份有限公司 | A kind of preparation method and its oil suspending agent of lycopene oil suspending agent |
| CN109700025B (en) * | 2018-12-14 | 2022-03-04 | 晨光生物科技集团股份有限公司 | Preparation method of lycopene oil suspension and oil suspension thereof |
| CN114451550A (en) * | 2021-12-21 | 2022-05-10 | 江苏艾兰得营养品有限公司 | Lutein defect type nano-structure lipid carrier and preparation method thereof |
| CN115812960A (en) * | 2022-11-09 | 2023-03-21 | 黑龙江八一农垦大学 | Preparation method of oil-based high-solubility non-oxygen-containing carotenoid |
| CN115844015A (en) * | 2022-12-06 | 2023-03-28 | 南昌大学 | Lycopene oil, lycopene preparation and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106213515A (en) | A kind of high bioavailability lycopene oral liquid product and preparation method | |
| Shi et al. | Nanostructured lipid carriers loaded with baicalin: an efficient carrier for enhanced antidiabetic effects | |
| Luo et al. | Fabrication of β-carotene nanoemulsion-based delivery systems using dual-channel microfluidization: Physical and chemical stability | |
| CN105596314B (en) | A kind of preparation method of the molten natural astaxanthin microcapsule formulation of high stability cold water | |
| Beg et al. | Development, optimization, and characterization of solid self-nanoemulsifying drug delivery systems of valsartan using porous carriers | |
| CN103406079B (en) | Do not use the method that organic solvent prepares cold water dispersion type carotenoid micro-capsule powder | |
| US8460638B2 (en) | Method of imaging with fluorescent microspheres | |
| CN105412016B (en) | A kind of enteric solid preparation and preparation method thereof containing lycopene, resveratrol or epiphysin | |
| Zhang et al. | Self-emulsifying drug delivery system and the applications in herbal drugs | |
| CN103251539B (en) | Nanostructured lipid carrier for composite skin lightener and preparation method of composite skin lightener | |
| Wagh et al. | Preparation and characterization of ketorolac tromethamine-loaded ethyl cellulose micro-/nanospheres using different techniques | |
| CN107205931A (en) | The method that the other amorphous solid dispersion of submicron order is prepared by co-precipitation | |
| CN102772337A (en) | Preparation method of composite whitening lipid nanoparticle emulsion | |
| CN102614091B (en) | Resveratrol nanostructured lipid carrier and preparation method thereof | |
| Brotons-Canto et al. | Zein nanoparticles improve the oral bioavailability of resveratrol in humans | |
| Chen et al. | Self-nano-emulsifying formulation of Sonchus oleraceus Linn for improved stability: Implications for phenolics degradation under in vitro gastro-intestinal digestion: Food grade drug delivery system for crude extract but not single compound | |
| CN106509902A (en) | Lycopene-loaded nano-emulsion and preparation method thereof | |
| JP6290899B2 (en) | Microcapsules containing plant-derived glycoproteins | |
| CN102860996A (en) | Method for preparing lycoypene microcapsule | |
| Marin et al. | Method to produce curcumin oil-in-water nanoemulsions as templates for drug carriers | |
| Xu et al. | Study on the relationship between lutein bioaccessibility and in vitro lipid digestion of nanostructured lipid carriers with different interface structures | |
| CN109568297A (en) | A kind of dihydromyricetin solid lipid nano granule and preparation method | |
| Cheong et al. | Palm‐based functional lipid nanodispersions: Preparation, characterization and stability evaluation | |
| Hong et al. | Preparation of nanostructured lipid drug delivery particles using microfluidic mixing | |
| CN103585137A (en) | Paeonol lyotropic liquid crystal self-emulsified preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161214 |